Washington Times Reports Bipartisan Bill would reclassify Marijuana as Schedule 3 Substance

Saturday, April 8, 2017

Bipartisan legislation proposed in the House on Thursday would make marijuana a Schedule 3 drug, removing cannabis from its current standing as a Schedule 1 substance alongside deadly contraband including ecstasy and heroin. 

By reclassifying weed in the same category as anabolic steroids, Congress would “make it easier for ill-patients and scientific and medical researchers to obtain marijuana,” the bill’s authors said in a statement Thursday.

How Canada's Marijuana Legalization Could Affect the U.S.

America's neighbor to the north is fast moving toward legalizing recreational marijuana nationwide, which would make Canada the second country in the world to do so. And the impact of having weed legalized on such a big scale, so close to home, may affect the future of pot in the United States. "There are those who sometimes regard Canada as the 51st state. It would be an important signal about the movement coming of age.

"There are those who sometimes regard Canada as the 51st state. It would be an important signal about the movement coming of age. It would add to the critical mass,” says Oregon Rep. Earl Blumenauer, a member of Congress' newly-formed Cannabis Caucus who is pushing to change the way the federal government treats the substance. And, he says: "It would shift the center of gravity."

Investing In A Different Kind Of Oil

In Canada, medical marijuana patients have the option to get their medication in dried form, as a concentrated oil or even fresh. Right now there are 38 approved licensed producers of medical marijuana of which only 22 produce oil. So why should this matter to Investors?

InMed's Pharmaceuticals Inc. 2017 Prospects

InMed Pharmaceuticals Inc. (CSE:IN, OTCQB:IMLFF) is a pre-clinical stage biopharmaceutical company specializing in the research, development and commercialization of cannabinoid-based therapies to treat human diseases with high unmet medical needs.